Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility
This cross-sectional study examines absolute neutrophil count–related racial and ethnic disparities in cancer clinical trial eligibility using Duffy null status.
Authors
- Lauren E. Merz (ORCID: https://orcid.org/0000-0002-6618-803X)
- Elad Sharon (ORCID: https://orcid.org/0000-0002-0044-9719)
- Thomas Walsh (ORCID: https://orcid.org/0000-0003-2620-6843)
- Stephen P. Hibbs (ORCID: https://orcid.org/0000-0002-3663-2742)
- Andrew Hantel (ORCID: https://orcid.org/0000-0001-9612-3643)
- Christopher S. Lathan (ORCID: https://orcid.org/0000-0003-4549-3040)
- Yating Wang (ORCID: https://orcid.org/0000-0003-4355-2190)
- Angel M. Cronin
Institutions
- Harvard University (US)
- Queen Mary University of London (GB)
- Dana-Farber Cancer Institute (US)
- Mass General Brigham (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1001/jamaoncol.2025.3869
- Citations
- 1
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.05